Generic Quality Assurance Topic At Japan’s Chuikyo Drug Price Reform Meeting
This article was originally published in PharmAsia News
The Japanese Central Social Insurance Medical Council’s committee on drug prices held a meeting June 12 to discuss the next drug price reforms, with one focus the need to assure the quality of generic drugs based on data.
You may also be interested in...
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.
Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning
Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.
Efficacy data were striking to committee members, but they want to ensure postmarketing plans gather adequate data to address safety questions.